Shares of Bio-Techne (TECH) were up Tuesday morning after the life sciences company said it prevailed in a second claim of reverse engineering of its antibodies by Mitlenyi Biotec.
The company said a court in Germany ruled that Miltenyi Biotec commercialized antibodies developed based on information obtained by reverse engineering certain branded antibodies of Bio-Techne.
The court found that Miltenyi has been marketing and selling those antibodies and determined that Bio-Techne is entitled to monetary damages related to sales of such antibodies, among other costs, Bio-Techne said.
Miltenyi didn't immediately respond to MT Newswires' request for comment.
Price: 75.65, Change: +1.40, Percent Change: +1.89
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。